Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease
Kahaly, George J. , Dolman, Peter J. , Wolf, Jan , Giers, Bert C. , Elflein, Heike M. , Jain, Amy Patel , Srinivasan, Ashok , Jordan, David R. , Eckstein, Anja , Pitz, Susanne, Vorländer, Christian, Wester, Sara T. , Nguyen, John , Tucker, Nancy, Nelson, Christine C. , Hardy, Isabelle , Serrano, Maravillas Abia , Tedeschi, Philip, Janes, Jonathan, Vue, Peter, Macias, William L., Stan, Marius N , Eckstein, Anja , Hadjiiski, Lubomir M. , Bradley, Elizabeth A. , Stan, Marius N. , Sales‐Sanz, Marco , Feldon, Steven E. , Tedeschi, Philip, Xu, Jing , Douglas, Raymond S

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | June 30, 2023 | Volume: 108 | Issue: 12 | Pages: 3122-3134

10.1210/clinem/dgad381 | PMID 37390454 Get It

AbstractContextInhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED).ObjectiveWe report the first clinical studies of an FcRn inhibitor, batoclimab, in TED.DesignProof-of-concept (POC) and randomized, double-blind placebo-controlled trials.SettingMulticenter.ParticipantsPatients with moderate-to-severe, active TED.InterventionIn the POC trial, patients received weekly subcutaneous injections of batoclimab 680 mg for 2 weeks, followed by 340 mg for 4 weeks. In the double-blind trial, patients were randomized 2:2:1:2 to weekly batoclimab (680 mg, 340 mg, 255 mg) or placebo for 12 weeks.Main OutcomeChange from baseline in serum anti-TSH-R-Ab and total IgG (POC); 12-week proptosis response (randomized trial).ResultsThe randomized trial was terminated because of an unanticipated increase in serum cholesterol; therefore, data from 65 of the planned 77 patients were analyzed. Both trials showed marked decreases in pathogenic anti-TSH-R-Ab and total IgG serum levels (P < .001) with batoclimab. In the randomized trial, there was no statistically significant difference with batoclimab vs placebo in proptosis response at 12 weeks, although significant differences were observed at several earlier timepoints. In addition, orbital muscle volume decreased (P < .03) at 12 weeks, whereas quality of life (appearance subscale) improved (P < .03) at 19 weeks in the 680-mg group. Batoclimab was generally well tolerated, with albumin reductions and increases in lipids that reversed upon discontinuation.ConclusionsThese results provide insight into the efficacy and safety of batoclimab and support its further investigation as a potential therapy for TED.
Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
Burack, Richard , Adlowitz, Diana G. , Spence, Janice M., Shadman, Mazyar , Spier, Catherine, Kaminski, Mark , Leonard, John P. , Smith, Sonali M. , Friedberg, Jonathan W. , Burack, W Richard , Adlowitz, Diana , Shadman, Mazyar , Smith, Sonali M , Li, Hongli , Rimsza, Lisa M. , LeBlanc, Michael

Mayo Clinic

Blood Advances | June 28, 2023 | Volume: 7 | Issue: 17 | Pages: 5082-5090

10.1182/bloodadvances.2022009467 | PMID 37379264 Get It

Abstract Although TP53 is commonly mutated in transformed follicular lymphoma, mutations are reported in <5% of pretreatment follicular lymphoma (FL) specimens. We assayed archival follicular B-cell non-Hodgkin lymphoma specimens from a completed clinical trial, Southwest Oncology Group S0016, a phase 3 randomized intergroup trial of CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisone) chemotherapy plus R-CHOP (rituximab-CHOP) compared with CHOP chemotherapy plus 131-iodine tositumomab (radioimmunotherapy [RIT]-CHOP). Subclonal TP53 mutations (median allele frequency 0.02) were found in 25% of diagnostic FL specimens and in 27% of a separate validation cohort. In the R-CHOP arm, pathogenic TP53 mutations were not associated with progression-free survival (PFS) (10-year PFS 43% vs 44%). In contrast, among patients with no detectable pathogenic TP53 mutation, RIT-CHOP was associated with a longer PFS than with R-CHOP (10-year PFS 67% vs 44%; hazard ratio = 0.49; P = .008). No relationship was detected between PFS and the extent of activation-induced cytidine deaminase (AICDA)–mediated heterogeneity. In summary, subclonal TP53 mutations are common in FL and are a distinct phenomenon from AICDA-mediated genetic heterogeneity. The absence of a detectable subclonal mutation in TP53 defined a population that particularly benefited from RIT.
Pharmacogenomic Overlap Between Antidepressant Treatment Response in Major Depression & Antidepressant Associated Treatment Emergent Mania in Bipolar Disorder
Núñez, Nicolás A. , Coombes, Brandon J. , Veldić, Marin , Moore, Katherine M. , Betcher, Hannah K. , Kung, Simon , Prieto, Miguel L. , Miola, Alessandro , Jenkins, Gregory D. , Batzler, Anthony , Frye, Mark A. , Veldic, Marin , Coombes, Brandon J , Beaupre, Lindsay Melhuish , Özerdem, Ayşegül , Gardea‐Resendez, Manuel , Romo‐Nava, Francisco , Bond, David J. , Singh, Balwinder , Fuentes, Manuel Enrique , Ercis, Mete , Sánchez-Ruiz, Jorge A. , Leung, Jonathan G. , Cuéllar‐Barboza, Alfredo B. , Tye, Susannah J. , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

No container title available | June 24, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3045012/v1 Get It

Abstract There is increasing interest in individualizing treatment selection for more than 25 regulatory approved treatments for major depressive disorder (MDD). Despite an inconclusive efficacy evidence base, antidepressants (ADs) are prescribed for the depressive phase of bipolar disorder with oftentimes an inadequate treatment response and or clinical concern for mood destabilization. This study explored the relationship between antidepressant response in MDD and antidepressant-associated treatment emergent mania (TEM) in bipolar disorder (BD). We conducted a genome-wide association study (GWAS) and polygenic score analysis of TEM and tested its association with a subset of BD-I patients treated with SSRIs or SNRIs. Our results did not identify any genome-wide significant variants although, we found that a higher polygenic score (PGS) for antidepressant response in MDD was associated with higher odds of TEM in BD. Future studies with larger transdiagnostic cohorts treated with antidepressants are encouraged to identify a neurobiological mechanism associated with a spectrum of depression improvement (response- emergent mania).
Complications Occurring Through 5 Years Following Primary Intraocular Lens Implantation for Pediatric Cataract
Yen, Kimberly G., Repka, Michael X. , Sutherland, Desirae R. , Haider, Kathryn M. , Kraker, Raymond T. , Galvin, Jennifer, Li, Zhuokai , Holmes, Jonathan M. , Group, Pediatric Eye Disease Investigator, Wallace, David K. , Enyedi, Laura B. , Jones, Sarah K., Hug, Denise, Stahl, Erin D., Dent, Rebecca J., Kong, Lingkun , Wang, Serena , Gallerson, Bryan K., Hutchinson, Amy K., Lenhart, Phoebe D. , Brower, Judy, Morrison, David G., Ruark, Scott T., Mets-Halgrimson, Rebecca, Yoon, Hawke , Hamidullah, Aaliyah, Anderson, Jill S., Holleschau, Ann M., Superstein, Rosanne , Bélanger, Caroline, Fallaha, Nicole, Hamel, Patrick , Thibeault, Maryse, Tamkins, Susanna M. , Park, Hee-Jung S., Trumler, Anya A., Liu, Xiaonong, Astle, William F., Sanders, Emi , McOwen, Diana C., Gray, Michael E. , Yang, Michael B. , Bowman, Corey S., Therriault, Margaret, Smith, Heather , Whitaker, Michele E., Örge, Faruk , Grigorian, A. Paula, Baird, Alicia M., Strominger, Mitchell B. , Klein, Shelley, Kemmer, Jacquelyn D., Neiman, Alexandra E., Mendoza, Myra N., Frohwein, Jill J., Bremer, Don L., Cassady, Cybil, Golden, Richard P., Jordan, Catherine O., Oravec, Sara A., Yanovitch, Tammy L. , Lunsford, Keven, Nye, Christina, Shea, Caroline, Stillman, SueAnn M., Iderstine, Stephen C. Van, Robertson, Elisa, Cruz, Oscar A., Ghadban, Rafif, Govreau, Dawn, Longmuir, Susannah Q. , Shan, Xiaoyan, Taylor, Kate , Powell, Christine, Hammond, Benjamin P., Gearinger, Matthew D., Czubinski, Andrea, Salvin, Jonathan, Fisher, Alicia, Lee, Katherine A., Brooks, Daniel , Schweinler, Bonita R., Sala, Nicholas A., Sala, Allyson M., Summers, Allison I. , Karr, Daniel J. , Wilson, Lorri B., Rauch, Paula K., O’Hara, Mary, Gandhi, Nandini, Hashmi, Tania, Colburn, Jeffrey, Dittman, Eileen, Whitfill, Charles R., Wheeler, Amy M., McCourt, Emily A. , Singh, Jasleen , Welnick, Nanastasia, Azar, Nathalie F., Baker, Joseph, Droste, Patrick J. , Peters, Robert J., Hilbrands, Jan, Pineles, Stacy L., Bernardo, Marianne J., Peterson, Edward, Peterson, Charla H., Kumar, Kartik , Melese, Ephrem, Lingua, Robert W., Grijalva, Jeff, Crouch, Earl R., Crouch, Earl R., Ventura, Gaylord, Anninger, William, Benson, Shawn L., Karp, Karen A. , Smith, Jordana M., Brickman-Kelleher, Jill, Ticho, Benjamin H., Khammar, Alexander J., Clausius, Deborah A., Guo, Suquin, Chamberlain, Carolyn, Schloff, Susan, Madigan, William P., Burkman, Donna, Ramsey, Jean E., McConnell, Kate H. , Friedman, Ilana, Rosado, José , Sauberan, Donald P., Hemberger, Jody C., Davis, Patricia L., Rudaitis, Indre, Lowery, Robert S., Cupit, Shawn, Bothun, Erick D. , Wernimont, Suzanne M., Neilsen, Rebecca A., Baran, Francine, Gladstone, Amy, Smith, Justin , Mellott, Mei, Kieser, Troy, Erzurum, S. Ayse , Colon, Beth, Shah, Birva, Quebbemann, Micaela, Austin, Darrell S., Boyle, Nicole M., Conner, Courtney L., Chandler, Danielle L. , Donahue, Quayleen, Fimbel, Brooke P., Robinson, Julianne L., Hercinovic, Amra, Hoepner, James E., Kaplon, Joseph D., Melia, Michele , Ortiz, Gillaine, Woodard, Victoria C., Stutz, Kathleen M., Everett, Donald F., Diener‐West, Marie , Baker, John D., Davis, Barry R. , Phelps, Dale L. , Poff, Stephen W., Tychsen, Lawrence , Bradfield, Yasmin S., Foster, Nicole C. , Plager, David A. , Silver, Jayne L., Weise, Katherine K., Verderber, Lisa C. , Dean, Trevano W., Campomanes, Alejandra G. de Alba , Young, Marielle P. , Rahmani, Bahram , Whitehead, George F., Lambert, Scott R. , Kurup, Sudhi P. , Kraus, Courtney L. , Hatt, Sarah R. , Cotter, Susan A. , Group, Pediatric Eye Disease Investigator, Freedman, Sharon F. , Prakalapakorn, Sasapin Grace , Ranaivo, Hantamalala Ralay , Areaux, Raymond G. , Chang, Ta Chen , Traboulsi, Elias I. , Ghasia, Fatema F. , Chen, Vicki, Rogers, David L. , LaRoche, G. Robert, Larson, Scott A. , Clarke, Michael W. , Hendricks, Dorothy H. , Jin, Jing , Brooks, Daniel, Rauch, Paula K., Baker, Joseph, Peterson, Edward, Crouch, Earl R., Suh, Donny Won , Christiansen, Stephen P. , Herlihy, Erin P. , Beck, Roy W. , Henderson, Robert J. , Wu, Rui , Saunders, Richard Anthony , Salchow, Daniel J. , Birch, Eileen E. , Manny, Ruth E. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | June 23, 2023 | Volume: 141 | Issue: 8 | Pages: 705

10.1001/jamaophthalmol.2023.2335 | PMID 37347490 Get It

Importance Lensectomy with primary intraocular lens (IOL) implantation is often used in the management of nontraumatic pediatric cataract, but long-term data evaluating the association of age and IOL location with the incidence of complications are limited. Objective To describe the incidence of complications and additional eye surgeries through 5 years following pediatric lensectomy with primary IOL implantation and association with age at surgery and IOL location. Design, Setting, and Participants This prospective cohort study used Pediatric Eye Disease Investigator Group cataract registry data from 61 institution- and community-based practices over 3 years (June 2012 to July 2015). Participants were children younger than 13 years without baseline glaucoma who had primary IOL implantation (345 bilateral and 264 unilateral) for nontraumatic cataract. Data analysis was performed between September 2021 and January 2023. Exposures Lensectomy with primary IOL implantation. Main Outcome and Measures Five-year cumulative incidence of complications by age at surgery (<2 years, 2 to <4 years, 4 to <7 years, and 7 to <13 years) and by IOL location (sulcus vs capsular bag) were estimated using Cox proportional hazards models. Results The cohort included 609 eyes from 491 children (mean [SD] age, 5.6 [3.3] years; 261 [53%] male and 230 [47%] female). Following cataract extraction with primary IOL implantation, a frequent complication was surgery for visual axis opacification (VAO) (cumulative incidence, 32%; 95% CI, 27%-36%). Cumulative incidence was lower with anterior vitrectomy at the time of IOL placement (12%; 95% CI, 8%-16%) vs without (58%; 95% CI, 50%-65%), and the risk of undergoing surgery for VAO was associated with not performing anterior vitrectomy (hazard ratio [HR], 6.19; 95% CI, 3.70-10.34; P < .001). After adjusting for anterior vitrectomy at lens surgery, there were no differences in incidence of surgery for VAO by age at surgery (<2 years, HR, 1.35 [95% CI, 0.63-2.87], 2 to <4 years, HR, 0.86 [95% CI, 0.44-1.68], 4 to <7 years, HR, 1.06 [95% CI, 0.72-1.56]; P = .74) or by capsular bag vs sulcus IOL fixation (HR, 1.22; 95% CI, 0.36-4.17; P = .75). Cumulative incidence of glaucoma plus glaucoma suspect by 5 years was 7% (95% CI, 4%-9%), which did not differ by age after controlling for IOL location and laterality. Conclusions and Relevance In this cohort study, a frequent complication following pediatric lensectomy with primary IOL was surgery for VAO, which was associated with primary anterior vitrectomy not being performed but was not associated with age at surgery or IOL location. The risk of glaucoma development across all ages at surgery suggests a need for long-term monitoring.
Outcomes of Reverse Total Shoulder Arthroplasty with Latissimus Dorsi Tendon Transfer for External Rotation Deficit
Hones, Keegan M. , Rakauskas, Taylor R. , King, Joseph J. , Wright, Thomas W. , Werthel, Jean-David , Hao, Kévin A. , King, Joseph J , Wright, Thomas W , Werthel, Jean-David , Schoch, Bradley S , Hao, Kevin A , Hones, Keegan M , Wright, Jonathan O. , Schoch, Bradley S.

Mayo Clinic

JBJS Reviews | June 20, 2023 | Volume: 11 | Issue: 6 | Pages: No page available

10.2106/jbjs.rvw.23.00048 | PMID 37339240 Get It

Background: Latissimus dorsi transfer (LDT) has been purported to restore motion in patients undergoing reverse shoulder arthroplasty (RSA) who have preoperative combined loss of forward elevation (FE) and external rotation (ER). This systematic review summarizes the available evidence for the functional outcomes and complications after RSA with LDT. Furthermore, the effect of implant design and whether a concomitant teres major transfer (TMT) was performed were studied. Methods: A systematic review was performed per Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We queried PubMed/MEDLINE, Embase, Web of Science, and Cochrane databases to identify articles reporting on LDT with RSA to restore ER. Our primary outcomes were ER, FE, Constant score, and complication incidence. Secondarily, we reported postoperative internal rotation (IR) and compared ER, FE, and Constant score based on lateralized versus medialized global implant design and whether concomitant TMT was performed. Results: Nineteen studies were evaluated; functional outcomes were assessed in 16 articles reporting on 258 RSAs (123 LDT, 135 LDT-TMT). Surgical indication was most commonly cuff tear arthropathy and massive irreparable cuff tear. Mean ER was −12° preoperatively and 25° postoperatively, FE was 72° preoperatively and 141° postoperatively. Mean postoperative Constant score was 65. Of 138 patients (8 studies) describing IR, only 25% reported a mean postoperative IR ≥L3. Subanalysis comparing lateralized versus medialized implants and whether TMT was concomitantly performed demonstrated no significant difference in postoperative ER, FE, and Constant score, nor preoperative to postoperative improvement in ER and FE. The complication rate was 14.1% (of 291 shoulders from 16 studies), including tear in the tendon transfer (n = 3), revision tendon repair (n = 1), nerve-related complication (n = 9), and dislocation (n = 9). Conclusions: RSA with LDT is a reliable option to restore motion, with a comparable complication rate with standard RSA. The use of medialized versus lateralized implants and whether the TM was concomitantly transferred may not influence clinical outcomes. Level of Evidence: Level IV . See Instructions for Authors for a complete description of levels of evidence.
Frequency of headache in emergency department patients with anaphylaxis: A cross‐sectional study
Zhang, Yuedan , Smith, Jonathan H., Vanmeter, Derek , Campbell, Ronna L. , Vanmeter, Derek E, Anderson, Joel R, Campbell, Ronna L , Mullan, Aidan F. , Anderson, Joel R.

Mayo Clinic

Headache: The Journal of Head and Face Pain | June 20, 2023 | Volume: 63 | Issue: 6 | Pages: 834-838

10.1111/head.14539 | PMID 37337682 Get It

Abstract Background Multiple anaphylaxis mediators have been demonstrated to provoke migraine‐like attacks following intravascular infusion, suggesting that anaphylaxis could cause headache; however, headache is rarely noted in anaphylaxis and is not included among diagnostic criteria. Objective Our study objectives were to estimate the frequency of headache among prospectively enrolled emergency department (ED) patients with anaphylaxis and assess the association of headache with patient and anaphylaxis characteristics. Methods A cross‐sectional study of ED patients aged ≥5 years who met anaphylaxis diagnostic criteria from January 8, 2020 to September 9, 2022 was conducted. The primary outcome of interest was headache frequency among patients who met at least one anaphylaxis criterion. We explored the association of headache with patient characteristics and anaphylaxis characteristics. Results We included 63 patients with anaphylaxis. In all, 17 (27%, 95% confidence interval [CI] 17%–40%) patients reported the presence of a headache. Female patients had more than a nine times increased odds of having headache (odds ratio [OR] 9.3, 95% CI 1.14–77.1, p = 0.016). Presentation with headache was associated with the presence of dyspnea (OR 5.5, 95% CI 1.56–19.7, p = 0.006). Conclusion Headache in anaphylaxis may be more common than previously recognized, especially in females. Larger prospective studies are needed to characterize headache as a marker of neurological involvement in anaphylaxis.
Patient- and Provider-Level Factors Associated With Telehealth Utilization Across a Multisite, Multiregional Cancer Practice From 2019 to 2021
Pritchett, Joshua C. , Dholakia, Ruchita, Ahn, Hannah H. , Khera, Nandita , Wilshusen, Laurie , Dronca, Roxana , Ticku, Jonathan, Leppin, Aaron L. , Tilburt, Jon C. , Haddad, Tufia C. , Moriarty, James P. , Ahn, Hannah H , Khera, Nandita , Dronca, Roxana S., Paludo, Jonas , Haddad, Tufia C , Pritchett, Joshua , Borah, Bijan J. , Huang, Ming , Paludo, Jonas

Mayo Clinic

JCO Oncology Practice | June 19, 2023 | Volume: 19 | Issue: 9 | Pages: 750-758

10.1200/op.23.00118 | PMID 37335959 Get It

PURPOSE In response to the COVID-19 pandemic, many cancer practices rapidly adopted telehealth services. However, there is a paucity of data regarding ongoing telehealth visit utilization beyond this initial response. The purpose of this study was to assess changes in variables associated with telehealth visit utilization over time. METHODS This is a cross-sectional, year-over-year, retrospective analysis of telehealth visits conducted across a multisite, multiregional cancer practice in the United States. Multivariable models examined the association of patient- and provider-level variables with telehealth utilization across outpatient visits conducted over three 8-week periods from July to August in 2019 (n = 32,537), 2020 (n = 33,399), and 2021 (n = 35,820). RESULTS The rate of telehealth utilization increased from <0.01% (2019) to 11% (2020) to 14% (2021). The most significant patient-level factors associated with increased telehealth utilization included nonrural residence and age ≤65 years. Among patients residing in rural settings, video visit utilization rates were significantly lower and phone visit utilization rates were significantly higher compared with patients from nonrural residences. Regarding provider-level factors, widening differences in telehealth utilization were observed at tertiary versus community-based practice settings. Increased telehealth utilization was not associated with duplicative care as per-patient and per-physician visit volumes in 2021 remained consistent with prepandemic levels. CONCLUSION We observed continuous expansion in telehealth visit utilization from 2020 to 2021. Our experiences suggest that telehealth can be integrated into cancer practices without evidence of duplicative care. Future work should examine sustainable reimbursement structures and policies to ensure accessibility of telehealth as a means to facilitate equitable, patient-centered cancer care.
Palliative Care Education in US Physical Medicine and Rehabilitation Residency Programs: Current Practices, Perceived Needs, and Barriers
Yeh, Jonathan C. , Ambady, Leena, Lewis, Ryan, Mehta, Ambereen K. , Asher, Arash , Engle, Jessica , Lewis, Ryan, Raj, Vishwa S.

Mayo Clinic

Journal of Palliative Medicine | June 19, 2023 | Volume: 26 | Issue: 8 | Pages: 1128-1132

10.1089/jpm.2022.0606 | PMID 37335750 Get It

Predicting disease progression and the need for tumor-directed treatment in tectal plate gliomas
Giesken, Max B. , Naylor, Ryan M. , Keating, Gesina F. , Schwartz, Jonathan , Schwartz, Jonathan D. , Bauman, Megan M. J. , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 18, 2023 | Volume: 32 | Issue: 3 | Pages: 332-342

10.3171/2023.4.peds22485 | PMID 37347621 Get It

OBJECTIVE Tectal plate gliomas are rare, slow-growing tumors of the midbrain that are discovered predominantly in the pediatric population. Because of their indolent nature, treatment mainly consists of observation and management of hydrocephalus. Unfortunately, a subset of tectal gliomas may exhibit tumor enlargement and disease progression. Currently, there are no established guidelines for predicting future progression of tectal gliomas or the need for tumor-directed treatment. In this paper, the authors present a large case series of tectal plate gliomas with the aim of determining early indicators of tumor progression and the need for tumor-directed treatment in a pediatric population, along with providing their experience in treating progressive tumors. METHODS A retrospective chart review of 170 patients diagnosed with tectal plate glioma from a single institution, of whom 67 were pediatric patients (≤ 18 years of age), was performed. Univariate analysis was used to determine statistically significant predictors of symptomatic disease progression requiring eventual tumor-directed therapy. RESULTS The median patient age of the full cohort was 24 years (range 0–73 years). Compared with the pediatric population, the adult population had more instances of incidental lesions (p < 0.001) and lower rates of hydrocephalus (50% vs 84%, p < 0.001). Of the pediatric patients who had ≥ 5 years of follow-up (n = 51), 12 (24%) experienced radiological progression and 13 (25%) required treatment for their tumor. The 1-year, 5-year, and 10-year radiographic progression-free survival (PFS) rates were 98%, 90%, and 86%, respectively. In univariate analysis, lesion involvement of the pons, moderate T1 hypointensity, and moderate contrast enhancement on baseline radiology were significantly associated with worse radiographic PFS. Alternatively, significant predictors of requiring tumor-directed treatment included extraocular eye movement abnormalities at presentation, involvement of the lesion beyond the tectum on baseline radiology, moderate T1 hypointensity, moderate contrast enhancement, and an increase in total lesion size during progression. At the most recent follow-up, 94% of the patients had stable/nonprogressive disease, 2% had progressive disease, and 4% died of tumor progression. CONCLUSIONS Patients who demonstrate radiographic progression may not necessarily experience clinical/symptomatic progression or require tumor-directed treatment. Certain patient presentation characteristics and baseline radiographic features may be predictive of worse radiographic PFS or the need for future tumor-directed treatment in the pediatric population. Typically, the natural history of these lesions lends to excellent long-term survival, even in patients who experience clinical progression, should appropriate treatment be initiated.
Management of Partial-Thickness Tears of the Distal Bicep Tendon: Evaluation of 111 Patients With 10-Year Follow-up
Till, Sara E., Wilbur, Ryan R. , Song, Bryant M. , Reinholz, Anna K., Johnson, Adam C. , Sanchez-Sotelo, Joaquin, Tagliero, Adam J. , Sánchez‐Sotelo, Joaquín , Barlow, Jonathan D. , Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | June 16, 2023 | Volume: 11 | Issue: 6 | Pages: No page available

10.1177/23259671231169202 | PMID 37342555 Get It

Background: There is a paucity of research on the management of partial-thickness tears of the distal bicep tendon, and even less is known about the long-term outcomes of this condition. Purpose: To identify patients with partial-thickness distal bicep tendon tears and determine (1) patient characteristics and treatment strategies, (2) long-term outcomes, and (3) any identifiable risk factors for progression to surgery or complete tear. Study Design: Case-control study; Level of evidence, 3. Methods: A fellowship-trained musculoskeletal radiologist identified patients diagnosed with a partial-thickness distal bicep tendon tear on magnetic resonance imaging between 1996 and 2016. Medical records were reviewed to confirm the diagnosis and record study details. Multivariate logistic regression models were created using baseline characteristics, injury details, and physical examination findings to predict operative intervention. Results: In total, 111 patients met inclusion criteria (54 treated operatively, 57 treated nonoperatively), with 53% of tears in the nondominant arm and a mean follow-up time after surgery of 9.7 ± 6.5 years. Only 5% of patients progressed to full-thickness tears during the study period, at a mean of 35 months after the initial diagnosis. Patients who were nonoperatively treated were less likely to miss time from work (12% vs 61%; P < .001) and missed fewer days (30 vs 97 days; P < .016) than those treated surgically. Multivariate regression analyses demonstrated increased risk of progression to surgery with older age at initial consult (unit odds ratio [OR], 1.1), tenderness to palpation (OR, 7.5), and supination weakness (OR, 24.8). Supination weakness at initial consult was a statistically significant predictor for surgical intervention (OR, 24.8; P = .001). Conclusion: Clinical outcomes were favorable for patients regardless of treatment strategy. Approximately 50% of patients were treated surgically; patients with supination weakness were 24 times more likely to undergo surgery than those without. Progression to full-thickness tear was a relatively uncommon reason for surgical intervention, with only 5% of patients progressing to full-thickness tears during the study period and the majority occurring within 3 months of initial diagnosis.